Figure 3.

Mefloquine (Mef) inhibits IKK activation. A, After treatment with 30 μmol/L mefloquine for different times, HCT116 and RKO cells were analyzed by immunoblotting of p‐IκBα, IκBα and GAPDH. B, HCT116 and RKO cells were treated with the indicated amounts of mefloquine overnight and then analyzed by immunoblotting of p‐IκBα, IκBα, p‐IKK, IKKα and IKKβ. GAPDH was used as a loading control. C, IKKβ activity analyses in a cell‐free system. Increasing concentrations of Mef or 60 nmol/L IKK‐16 were incubated with the recombinant IKKβ. Kinase activity of IKKβ was then determined. D, Empty vector (EV) or Flag‐CA‐IKKβ plasmids were transfected into HCT116 cells, which were lysed for immunoblotting against Flag, p‐IκBα, IκBα and GAPDH. E, After transfection with EV or Flag‐CA‐IKKβ plasmids for 24 h, HCT116 cells were treated with the indicated concentrations of mefloquine overnight and then analyzed by immunoblotting against p‐IκBα, IκBα, p‐p65, p65, Flag and GAPDH. IKK, IκB kinase